Lynx1 Capital Management LP, Ten Percent Owner at TScan Therapeutics, holds 1.54M shares in Korro Bio (Ticker: KRRO), holds 8.02M shares in TScan Therapeutics (Ticker: TCRX), holds 8.96M shares in Cullinan Management (Ticker: CGEM). Most recently, Lynx1 Capital Management LP Bought ― shares of Korro Bio on Apr 02, 2026 for an estimated value of $5.51K.
What was Lynx1 Capital Management LP’s latest transaction?
Lynx1 Capital Management LP latest transaction was an Informative Buy of $5.51K.
What was Lynx1 Capital Management LP's most profitable transaction?
Lynx1 Capital Management LP’s most profitable transaction was an Informative Buy of CGEM stock on October 10, 2025. The return on the trade was 82.20%.
What is Lynx1 Capital Management LP's role in TScan Therapeutics?
Lynx1 Capital Management LP's role in TScan Therapeutics is Ten Percent Owner.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.